Congenital Disorders of Glycosylation
A diverse group of inherited disorders affecting the attachment of sugar chains to proteins and lipids, leading to multisystem involvement that ranges widely in severity depending on the specific gene affected.
- Over 150 Known Subtypes
- Mostly Autosomal Recessive Inheritance
- Multidisciplinary, Subtype-Specific Care
- Known Subtypes
- 150+ Genes Identified
- Most Common Subtype
- PMM2-CDG (CDG-Ia)
- Inheritance Pattern
- Mostly Autosomal Recessive (some X-linked)
- Management Anchor
- Multidisciplinary, Subtype-Specific Care
Condition Overview
Congenital disorders of glycosylation (CDG) are a large and growing group of inherited metabolic disorders caused by defects in the pathways that attach sugar chains (glycans) to proteins and lipids. Glycosylation is essential for the proper folding, stability, and function of many proteins throughout the body, so defects can affect multiple organ systems simultaneously.
More than 150 distinct genetic subtypes have been identified, the most common being PMM2-CDG. Clinical presentation varies enormously between subtypes and even within the same subtype, ranging from mild learning difficulties to severe multisystem disease involving the brain, liver, gut, immune system, and coagulation pathways.
Because of this heterogeneity, accurate subtype identification through specialized testing is essential to guide prognosis discussions and any subtype-specific management options that exist.
Types and Subtypes
CDG subtypes are classified by which step of the glycosylation pathway is affected and by the specific gene involved.
Symptoms and Signs
Symptoms vary widely by subtype but commonly involve neurological, gastrointestinal, and growth-related features.
Causes and Risk Factors
CDG results from inherited variants in any of more than 150 genes involved in glycan synthesis, attachment, or processing.
Diagnosis and Investigations
Diagnosis combines biochemical screening for abnormal glycosylation patterns with genetic confirmation of the specific subtype.
Disease Classification and Risk Stratification
CDG does not use a tumor-style staging system. Classification is instead by molecular subtype, and clinical risk is stratified by the pattern and severity of organ involvement specific to that subtype.
Standard Treatment Options
Management is largely supportive and multidisciplinary, with a small number of subtypes having targeted metabolic therapies.
Advanced and Emerging Approaches
Most CDG subtypes currently lack a disease-specific cure, but research into targeted approaches is active for several subtypes.
Targeted Metabolic Supplementation
Mannose Supplementation (MPI-CDG)
An established targeted therapy for MPI-CDG that can improve gastrointestinal and hepatic manifestations.
Precision Medicine
Gene-Specific Investigational Therapies
Research is exploring substrate supplementation, gene therapy, and other molecularly targeted approaches for select CDG subtypes.
Biomarkers and Laboratory Monitoring
Biomarkers in CDG are used primarily for diagnosis and organ-system monitoring rather than for cancer-style prognostic staging.
When a Second Opinion May Be Important
Given the rarity and heterogeneity of CDG, expert input from a specialized metabolic genetics center is valuable at multiple points.
Clinical Trials and Research
Outlook and Key Outcome Factors
Outlook in CDG varies enormously depending on the specific subtype and the extent of organ involvement, making individualized assessment essential.
Supportive Care and Living with CDG
Because CDG affects multiple organ systems, supportive care is typically coordinated across several specialties.
How CancerFax Helps You Explore Treatment Options
CancerFax can help families coordinate medical report review, connect with metabolic genetics specialists for second opinions, and identify experienced multidisciplinary centers for ongoing CDG management.
Get a free case reviewFrequently Asked Questions
It is one of a large group of inherited disorders that impair how sugar chains are attached to proteins and lipids, affecting protein function across multiple organ systems.
They are caused by inherited variants in any of more than 150 different genes involved in the glycosylation pathway, most often in an autosomal recessive pattern.
PMM2-CDG, also known as CDG-Ia, is the most frequently diagnosed subtype.
Diagnosis typically begins with transferrin glycoform analysis and is confirmed through genetic testing of the specific gene involved.
Most subtypes are managed supportively across multiple specialties; a small number, such as MPI-CDG, have a targeted treatment in the form of mannose supplementation.
No, while many subtypes cause developmental delay or neurological symptoms, some primarily affect other organs such as the liver or gastrointestinal tract.
Most subtypes present in infancy or early childhood, though milder forms may not be recognized until later.
For autosomal recessive subtypes, parents of an affected child are carriers with an approximate 25% recurrence risk per pregnancy; genetic counseling is recommended.
No, CDG is a group of inherited glycosylation disorders and is not itself a form of cancer, though it is grouped here as a genetic disorder requiring specialized multidisciplinary care.
Yes. CancerFax can help coordinate medical report review, facilitate second opinions with metabolic genetics specialists, and assist with matching families to experienced multidisciplinary centers for ongoing care.
Get Expert Guidance for Congenital Disorders of Glycosylation
CancerFax can help connect you with metabolic genetics specialists, support second opinions, and guide you through ongoing care decisions.